U.S., Sept. 5 -- ClinicalTrials.gov registry received information related to the study (NCT07154381) titled 'Hybrid Florbetaben PET/MRI for Imaging of Cardiac Amyloidosis' on May 20.
Brief Summary: Exploration of prognostic parameters in 18F-Florbetaben PET/MRI in patients with cardiac amyloidosis. The clinical endpoints are defined as occurence of major adverse cardiac events (MACE) in amyloidosis patients. Additionally, MACE outcome stratified by PET parameters will be evaluated and individual parameters of the imaging techniques will be compared to each other (PET, MRI or echocardiography).
Study Start Date: Dec. 09, 2019
Study Type: OBSERVATIONAL
Condition:
Cardiac Amyloidosis
Recruitment Status: RECRUITING
Sponsor: University Ho...